Literature DB >> 17601929

Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations.

Richard H Scott1, Tessa Homfray, Nicola L Huxter, Sally G Mitton, Ruth Nash, Mike N Potter, Donna Lancaster, Nazneen Rahman.   

Abstract

Familial non-Hodgkin lymphoma (NHL) is rare and in most cases, no underlying cause is identifiable. We report homozygous truncating mutations in the mismatch repair gene MSH2 (226C-->T; Q76X) in three siblings who each developed T-cell NHL in early childhood. All three children had hyperpigmented and hypopigmented skin lesions. Constitutional biallelic MSH2 mutations have previously been reported in five individuals, all of whom developed malignancy in childhood. Familial lymphoma has not been reported in this context or in association with biallelic mutations in the other mismatch repair genes MLH1, MSH6 or PMS2. In addition, hypopigmented skin lesions have not previously been reported in biallelic MSH2 carriers. Our findings therefore expand the spectrum of phenotypes associated with biallelic MSH2 mutations and identify a new cause of familial lymphoma. Moreover, the diagnosis has important management implications as it allows the avoidance of chemotherapeutic agents likely to be ineffective and mutagenic in the proband, and the provision of cascade genetic testing and tumour screening for relatives.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17601929      PMCID: PMC2597999          DOI: 10.1136/jmg.2007.048942

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

Review 1.  Familial aggregation of hematopoietic malignancies and risk of non-Hodgkin's lymphoma.

Authors:  M S Linet; L M Pottern
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

2.  A novel MSH2 germline mutation in homozygous state in two brothers with colorectal cancers diagnosed at the age of 11 and 12 years.

Authors:  Annegret Müller; Hans K Schackert; Bettina Lange; Josef Rüschoff; Laslow Füzesi; Joerg Willert; Peter Burfeind; Parantu Shah; Heinz Becker; Joerg Thomas Epplen; Susanne Stemmler
Journal:  Am J Med Genet A       Date:  2006-02-01       Impact factor: 2.802

Review 3.  Mechanisms of therapy-related carcinogenesis.

Authors:  James M Allan; Lois B Travis
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

Review 4.  Nijmegen breakage syndrome.

Authors:  I van der Burgt; K H Chrzanowska; D Smeets; C Weemaes
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

5.  Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6.

Authors:  John R Ostergaard; Lone Sunde; Henrik Okkels
Journal:  Am J Med Genet A       Date:  2005-12-01       Impact factor: 2.802

6.  The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

Authors:  Wilhelm Woessmann; Kathrin Seidemann; Georg Mann; Martin Zimmermann; Birgit Burkhardt; Ilske Oschlies; Wolf-Dieter Ludwig; Thomas Klingebiel; Norbert Graf; Bernd Gruhn; Heribert Juergens; Felix Niggli; Reza Parwaresch; Helmut Gadner; Hansjoerg Riehm; Martin Schrappe; Alfred Reiter
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

7.  Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation.

Authors:  Steven Gallinger; Melyssa Aronson; Katayoon Shayan; Elyanne M Ratcliffe; Justin T Gerstle; Patricia C Parkin; Heidi Rothenmund; Marina Croitoru; Ewa Baumann; Peter R Durie; Rosanna Weksberg; Aaron Pollett; Robert H Riddell; Bo Y Ngan; Ernest Cutz; Alain E Lagarde; Helen S L Chan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

Review 8.  Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review).

Authors:  Andre Fedier; Daniel Fink
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

9.  Familial T-cell lymphoblastic lymphoma: association with Von Recklinghausen neurofibromatosis and Gardner syndrome.

Authors:  J Kaplan; B Cushing; C H Chang; R Poland; J Roscamp; E Perrin; N Bhaya
Journal:  Am J Hematol       Date:  1982-05       Impact factor: 10.047

10.  Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.

Authors:  Anindita Roy; Mike Bradburn; Anthony V Moorman; Julie Burrett; Sharon Love; Sally E Kinsey; Chris Mitchell; Ajay Vora; Tim Eden; John S Lilleyman; Ian Hann; Vaskar Saha
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

View more
  12 in total

1.  Constitutional mismatch repair-deficiency syndrome.

Authors:  Katharina Wimmer; Christian P Kratz
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.

Authors:  Melyssa Aronson; Steven Gallinger; Zane Cohen; Shlomi Cohen; Rina Dvir; Ronit Elhasid; Hagit N Baris; Revital Kariv; Harriet Druker; Helen Chan; Simon C Ling; Paul Kortan; Spring Holter; Kara Semotiuk; David Malkin; Roula Farah; Alain Sayad; Brandie Heald; Matthew F Kalady; Lynette S Penney; Andrea L Rideout; Mohsin Rashid; Linda Hasadsri; Pavel Pichurin; Douglas Riegert-Johnson; Brittany Campbell; Doua Bakry; Hala Al-Rimawi; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Uri Tabori; Carol Durno
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

3.  Impact of 226C>T MSH2 gene mutation on cancer phenotypes in two HNPCC-associated highly-consanguineous families from Kuwait: emphasis on premarital genetic testing.

Authors:  Makia J Marafie; Sadiqa Al-Awadi; Fatemah Al-Mosawi; Alaa Elshafey; Waleed Al-Ali; Fahd Al-Mulla
Journal:  Fam Cancer       Date:  2009-08-08       Impact factor: 2.375

4.  MSH2/MSH6 complex promotes error-free repair of AID-induced dU:G mispairs as well as error-prone hypermutation of A:T sites.

Authors:  Sergio Roa; Ziqiang Li; Jonathan U Peled; Chunfang Zhao; Winfried Edelmann; Matthew D Scharff
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

Review 5.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

6.  Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries.

Authors:  M Fallah; E Kharazmi; E Pukkala; S Tretli; J H Olsen; L Tryggvadottir; K Sundquist; K Hemminki
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

7.  Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome.

Authors:  Laura Giunti; Valentina Cetica; Ugo Ricci; Sabrina Giglio; Iacopo Sardi; Milena Paglierani; Elena Andreucci; Massimiliano Sanzo; Marco Forni; Anna Maria Buccoliero; Lorenzo Genitori; Maurizio Genuardi
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

8.  Heritable T-cell malignancy models established in a zebrafish phenotypic screen.

Authors:  J K Frazer; N D Meeker; L Rudner; D F Bradley; A C H Smith; B Demarest; D Joshi; E E Locke; S A Hutchinson; S Tripp; S L Perkins; N S Trede
Journal:  Leukemia       Date:  2009-06-11       Impact factor: 11.528

9.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

Review 10.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.